SynthesisBMC nephrology2017
Erythropoiesis stimulating agents and reno-protection: a meta-analysis.
Synthesis in BMC nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Erythropoiesis-stimulating agents for preventing acute kidney injury.The Cochrane database of systematic reviews · 2024Pooled it
- Effects of Jianpi Bushen Therapy for Treatment of CKD Anemia: A Meta-Analysis of Randomized Controlled Trials.Frontiers in pharmacology · 2020Pooled it
- Machine learning-based prediction of acute kidney injury after intracerebral hemorrhage: Comparison of multiple model approaches.Medicine · 2025Article
- Anemia and iron deficiency in post-kidney transplantation: an unsolved challenge.Clinical kidney journal · 2025Review
- Renoprotective Effects of Daprodustat in Patients with Chronic Kidney Disease and Renal Anemia.International journal of molecular sciences · 2024Article
- Tubular Endogenous Erythropoietin Protects Renal Function against Ischemic Reperfusion Injury.International journal of molecular sciences · 2024Article
- Anemia and Hypoxia Impact on Chronic Kidney Disease Onset and Progression: Review and Updates.Cureus · 2023Review
- The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors.Clinical kidney journal · 2023Review
- Pharmacological Nephroprotection in Non-Diabetic Chronic Kidney Disease-Clinical Practice Position Statement of the Polish Society of Nephrology.Journal of clinical medicine · 2023Review
- Treatment Options for Anemia in Kidney Transplant Patients: A Review.Kidney medicine · 2023Review
- Risk factors and current state of therapy for anemia after kidney transplantation.Frontiers in medicine · 2023Review
- A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study.Kidney international reports · 2021Article
- Erythropoietin in Lupus: Unanticipated Immune Modulating Effects of a Kidney Hormone.Frontiers in immunology · 2021Review
- Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease.Current opinion in nephrology and hypertension · 2020Review
- Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2020Review
- Advances in Understanding the Effects of Erythropoietin on Renal Fibrosis.Frontiers in medicine · 2020Review
- Prolyl hydroxylase domain inhibitors: a new era in the management of renal anemia.Annals of translational medicine · 2019Article
- Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2019Review
- Plasmatic Klotho and FGF23 Levels as Biomarkers of CKD-Associated Cardiac Disease in Type 2 Diabetic Patients.International journal of molecular sciences · 2019Article
- Risk Factors for Recurrent Acute Kidney Injury in a Large Population-Based Cohort.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundErythropoiesis stimulating agents (ESAs) were proposed to enhance survival of renal tissues through direct effects via activation of EPO receptors on renal cells resulting in reduced cell apoptosis, or indirect effects via increased oxygen delivery due to increased numbers of Hb containing red blood cells. Thus through several mechanisms there may be benefit of ESA administration on kidney disease progression and kidney function in renal patients. However conflicting ESA reno-protection outcomes have been reported in both pre-clinical animal studies and human clinical trials. To better understand the potential beneficial effects of ESAs on renal-patients, meta-analyses of clinical trials is needed.
methodsLiterature searches and manual searches of references lists from published studies were performed. Controlled trials that included ESA treatment on renal patients with relevant renal endpoints were selected.
resultsThirty two ESA controlled trials in 3 categories of intervention were identified. These included 7 trials with patients who had a high likelihood of AKI, 7 trials with kidney transplant patients and 18 anemia correction trials with chronic kidney disease (predialysis) patients. There was a trend toward improvement in renal outcomes in the ESA treated arm of AKI and transplant trials, but none reached statistical significance. In 12 of the anemia correction trials, meta-analyses showed no difference in renal outcomes with the anemia correction but both arms received some ESA treatment making it difficult to assess effects of ESA treatment alone. However, in 6 trials the low Hb arm received no ESAs and meta-analysis also showed no difference in renal outcomes, consistent with no benefit of ESA/ Hb increase.
conclusionsMost ESA trials were small with modest event rates. While trends tended to favor the ESA treatment arm, these meta-analyses showed no reduction of incidence of AKI, no reduction in DGF or improvement in 1-year graft survival after renal transplantation and no significant delay in progression of CKD. These results do not support significant clinical reno-protection by ESAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.